Clover Biopharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Clover Biopharmaceuticals, Inc.
In a significant policy shift and following recent public unrest, China now appears to be moving away from its strict "COVID Zero" restrictions to salvage a floundering economy hard hit by repeated lockdowns, as part of which it is looking to accelerate the approval of new vaccines and increase vaccination rates in the elderly.
China has cleared for sale the world's first inhaled vaccine for COVID-19, as China continues to face challenges to its strict "COVID Zero" policies, including a new extended lockdown in a major city, ahead of the upcoming high-stakes National Congress.
A clutch of Chinese biopharma firms, including I-Mab, Lepu and Clover, are having second thoughts on some of their clinical development programs to conserve cash amid a funding squeeze.
CanSino and Zhifei have received the regulatory green light for their respective COVID-19 booster shots in China and an estimated $1.3bn vaccine market is now up for grabs. Domestic contenders are set to elbow each other in the sector with a range of viral vector, recombinant protein and mRNA-based jabs.
- Large Molecule
- Other Names / Subsidiaries
- Sichuan Clover Biopharmaceuticals Inc.
- Clover Biopharmaceuticals AUS Pty Ltd
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.